"Everolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.
| Descriptor ID |
D000068338
|
| MeSH Number(s) |
D02.540.505.760.500
|
| Concept/Terms |
Everolimus- Everolimus
- SDZ RAD
- RAD, SDZ
- SDZ-RAD
- 40-O-(2-hydroxyethyl)-rapamycin
|
Below are MeSH descriptors whose meaning is more general than "Everolimus".
Below are MeSH descriptors whose meaning is more specific than "Everolimus".
This graph shows the total number of publications written about "Everolimus" by people in this website by year, and whether "Everolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 2 | 2 |
| 2014 | 0 | 3 | 3 |
| 2015 | 2 | 2 | 4 |
| 2016 | 3 | 0 | 3 |
| 2017 | 42 | 20 | 62 |
| 2018 | 35 | 21 | 56 |
| 2019 | 8 | 14 | 22 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Everolimus" by people in Profiles.
-
Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic. Seizure. 2021 10; 91:271-272.
-
Clinical course of COVID-19 disease in immunosuppressed renal transplant patients Turk J Med Sci. 2021 04 30; 51(2):428-434.
-
Complete recovery from COVID-19 of a kidney-pancreas transplant recipient: potential benefit from everolimus? BMJ Case Rep. 2021 Jan 11; 14(1).
-
Liver transplant immunosuppression during the covid-19 pandemic. Gastroenterol Hepatol. 2020 Oct; 43(8):457-463.
-
Prognostic performance of the Society of Thoracic Surgeons risk score in patients with left main coronary artery disease undergoing revascularisation: a post hoc analysis of the EXCEL trial. EuroIntervention. 2020 May 20; 16(1):36-43.
-
Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics. Am J Transplant. 2020 Jul; 20(7):1896-1901.
-
Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study. JAMA Cardiol. 2019 12 01; 4(12):1261-1269.
-
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. N Engl J Med. 2019 11 07; 381(19):1820-1830.
-
Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial. Circulation. 2019 12 03; 140(23):1895-1903.
-
Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial. EuroIntervention. 2019 Sep 20; 15(7):607-614.